Disease on EC 1.1.1.62 - 17beta-estradiol 17-dehydrogenase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
17beta-estradiol 17-dehydrogenase deficiency
Deleterious missense mutations and silent polymorphism in the human 17beta-hydroxysteroid dehydrogenase 3 gene (HSD17B3).
Stromal cells of endometriosis fail to produce paracrine factors that induce epithelial 17beta-hydroxysteroid dehydrogenase type 2 gene and its transcriptional regulator Sp1: a mechanism for defective estradiol metabolism.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
3beta-hydroxysteroid dehydrogenase/delta5-->4-isomerase activity associated with the human 17beta-hydroxysteroid dehydrogenase type 2 isoform.
46, XY Disorders of Sex Development
Deleterious missense mutations and silent polymorphism in the human 17beta-hydroxysteroid dehydrogenase 3 gene (HSD17B3).
Abortion, Spontaneous
Evidence for association of the rs605059 polymorphism of HSD17B1 gene with recurrent spontaneous abortions.
Adenoma
17Beta-hydroxysteroid dehydrogenase type 1, 2, 3, and 4 expression and enzyme activity in human anterior pituitary adenomas.
Estrogen receptors (alpha and beta) and 17beta-hydroxysteroid dehydrogenase type 1 and 2 in thyroid disorders: possible in situ estrogen synthesis and actions.
Adenomyosis
Adenomyosis: the pathophysiology of an oestrogen-dependent disease.
Alzheimer Disease
Polymorphisms in HSD17B1: Early Onset and Increased Risk of Alzheimer's Disease in Women with Down Syndrome.
Ataxia
Mutations in the DBP-deficiency protein HSD17B4 cause ovarian dysgenesis, hearing loss, and ataxia of Perrault Syndrome.
Next generation sequencing with copy number variant detection expands the phenotypic spectrum of HSD17B4-deficiency.
Severe manifestation of Leber's hereditary optic neuropathy due to 11778G>A mtDNA mutation in a female with hypoestrogenism due to Perrault syndrome.
Breast Diseases
New development in intracrinology of breast carcinoma.
Polymorphisms in steroid hormone biosynthesis genes and risk of breast cancer and fibrocystic breast conditions in Chinese women.
Breast Neoplasms
1-[(Benzofuran-2-yl)phenylmethyl]triazoles as steroidogenic inhibitors: synthesis and in vitro inhibition of human placental CYP19 aromatase.
17-beta-Hydroxysteroid dehydrogenase type 1: computational design of active site inhibitors targeted to the Rossmann fold.
17beta-hydroxysteroid dehydrogenase 14 affects estradiol levels in breast cancer cells and is a prognostic marker in estrogen receptor-positive breast cancer.
17Beta-hydroxysteroid dehydrogenase enzymes and breast cancer.
17Beta-hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters.
17beta-hydroxysteroid dehydrogenase type 1 is an independent prognostic marker in breast cancer.
17beta-hydroxysteroid dehydrogenase type 1 modulates breast cancer protein profile and impacts cell migration.
17beta-hydroxysteroid dehydrogenase type 1 stimulates breast cancer by dihydrotestosterone inactivation in addition to estradiol production.
17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer.
17Beta-hydroxysteroid dehydrogenase type 12 in human breast carcinoma: a prognostic factor via potential regulation of fatty acid synthesis.
17ss-Hydroxysteroid dehydrogenase type 1 as predictor of tamoxifen response in premenopausal breast cancer.
A concerted, rational design of type 1 17beta-hydroxysteroid dehydrogenase inhibitors: estradiol-adenosine hybrids with high affinity.
A new polymorphism in the coding region of exon four in HSD17B2 in relation to risk of sporadic and hereditary breast cancer.
Abnormal expression of 17beta-hydroxysteroid dehydrogenases in breast cancer predicts late recurrence.
Acetylation targets HSD17B4 for degradation via the CMA pathway in response to estrone.
Active site analysis of 17beta-hydroxysteroid dehydrogenase type 1 enzyme complexes with SPROUT.
African American-preponderant single nucleotide polymorphisms (SNPs) and risk of breast cancer.
Amplification of HSD17B1 and ERBB2 in primary breast cancer.
Amplification of HSD17B1 has prognostic significance in postmenopausal breast cancer.
Analysis of 17beta-hydroxysteroid dehydrogenase types 5, 7, and 12 genetic sequence variants in breast cancer cases from French Canadian Families with high risk of breast and ovarian cancer.
Aromatase localization in human breast cancer tissues: possible interactions between intratumoral stromal and parenchymal cells.
Binary and ternary crystal structure analyses of a novel inhibitor with 17beta-HSD type 1: a lead compound for breast cancer therapy.
Building a multigenic model of breast cancer susceptibility: CYP17 and HSD17B1 are two important candidates.
Characterization of HSD17B1 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer.
Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
Design, Synthesis, and Biological Evaluation of (Hydroxyphenyl)naphthalene and -quinoline Derivatives: Potent and Selective Nonsteroidal Inhibitors of 17beta-Hydroxysteroid Dehydrogenase Type 1 (17beta-HSD1) for the Treatment of Estrogen-Dependent Diseases.
Dietary isoflavone intake, polymorphisms in the CYP17, CYP19, 17beta-HSD1, and SHBG genes, and risk of breast cancer in case-control studies in Japanese, Japanese Brazilians, and non-Japanese Brazilians.
Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries.
Effect of nomegestrol acetate on estrogen biosynthesis and transformation in MCF-7 and T47-D breast cancer cells.
Effect of retinoic acid and palm oil carotenoids on oestrone sulphatase and oestradiol-17beta hydroxysteroid dehydrogenase activities in MCF-7 and MDA-MB-231 breast cancer cell lines.
Estradiol and estrone C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: blocking of ER+ breast cancer cell proliferation induced by estrone.
Estradiol-independent modulation of breast cancer transcript profile by 17beta-hydroxysteroid dehydrogenase type 1.
Estrogen-related genes and their contribution to racial differences in breast cancer risk.
Estrone C15 derivatives--a new class of 17beta-hydroxysteroid dehydrogenase type 1 inhibitors.
Evaluation of inhibitors for 17beta-hydroxysteroid dehydrogenase type 1 in vivo in immunodeficient mice inoculated with MCF-7 cells stably expressing the recombinant human enzyme.
Expression of 17beta-hydroxysteroid dehydrogenase type 2 and type 5 in breast cancer and adjacent non-malignant tissue: a correlation to clinicopathological parameters.
Expression of aromatase and 17beta-hydroxysteroid dehydrogenase types 1, 7 and 12 in breast cancer An immunocytochemical study.
Expression of COX-2 and steroid converting enzymes in breast cancer.
Focused Libraries of 16-Substituted Estrone Derivatives and Modified E-Ring Steroids: Inhibitors of 17ss-Hydroxysteroid Dehydrogenase Type 1.
Gene-body hypermethylation of ATM in peripheral blood DNA of bilateral breast cancer patients.
Genomic data on breast cancer transcript profile modulation by 17beta-hydroxysteroid dehydrogenase type 1 and 17-beta-estradiol.
Haplotype analysis of the HSD17B1 gene and risk of breast cancer: a comprehensive approach to multicenter analyses of prospective cohort studies.
High expression of steroid sulfatase mRNA predicts poor prognosis in patients with estrogen receptor-positive breast cancer.
Hormone replacement therapy and cancers: the biological roles of estrogen and progestin in tumorigenesis are different between the endometrium and breast.
HSD17B1 and CYP17 polymorphisms and breast cancer risk among Chinese women in Singapore.
HSD17B1 gene polymorphisms and risk of endometrial and breast cancer.
HSD17B1 Genetic Variants and Hormone Receptor-Defined Breast Cancer.
Human hydroxysteroid (17-beta) dehydrogenase 1 expression enhances estrogen sensitivity of MCF-7 breast cancer cell xenografts.
Identification of Hydroxysteroid (17?) dehydrogenase type 12 (HSD17B12) as a CD8(+) T-cell-defined human tumor antigen of human carcinomas.
In situ production of sex steroids in human breast carcinoma.
In vivo and in vitro expression of steroid-converting enzymes in human breast tumours: associations with interleukin-6.
Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients.
Increased intratumoral androgens in human breast carcinoma following aromatase inhibitor exemestane treatment.
Insights in 17beta-HSD1 enzyme kinetics and ligand binding by dynamic motion investigation.
Involvement of up-regulation of 17beta-hydroxysteroid dehydrogenase type 1 in maintenance of intratumoral high estradiol levels in postmenopausal breast cancers.
Ligand-based NMR spectra demonstrate an additional phytoestrogen binding site for 17beta-hydroxysteroid dehydrogenase type 1.
Mutation analysis and characterization of HSD17B2 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer.
New development in intracrinology of breast carcinoma.
Polymorphism Thr160Thr in SRD5A1, involved in the progesterone metabolism, modifies postmenopausal breast cancer risk associated with menopausal hormone therapy.
Polymorphisms in steroid hormone biosynthesis genes and risk of breast cancer and fibrocystic breast conditions in Chinese women.
Possible difference in frequencies of genetic polymorphisms of estrogen receptor alpha, estrogen metabolism and P53 genes between estrogen receptor-positive and -negative breast cancers.
Progestins and cancer.
Ratio of 17HSD1 to 17HSD2 Protein Expression Predicts the Outcome of Tamoxifen Treatment in Postmenopausal Breast Cancer Patients.
Role of BRCA1, HSD17B1 and HSD17B2 methylation in breast cancer tissue.
Selective estrogen enzyme modulator actions of melatonin in human breast cancer cells.
Selective inhibition of 17beta-hydroxysteroid dehydrogenase type 1 (17betaHSD1) reduces estrogen responsive cell growth of T47-D breast cancer cells.
Sex steroid-producing enzymes in human breast cancer.
Species used for drug testing reveal different inhibition susceptibility for 17beta-hydroxysteroid dehydrogenase type 1.
Structure and function of 17beta-hydroxysteroid dehydrogenase type 1 and type 2.
Structure of the ternary complex of human 17beta-hydroxysteroid dehydrogenase type 1 with 3-hydroxyestra-1,3,5,7-tetraen-17-one (equilin) and NADP+.
Structure-activity study in the class of 6-(3'-hydroxyphenyl)naphthalenes leading to an optimization of a pharmacophore model for 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors.
The association between HSD17B1 Ser312Gly polymorphism and breast cancer risk: a meta-analysis including 31,053 subjects.
The contribution of 17beta-hydroxysteroid dehydrogenase type 1 to the estradiol-estrone ratio in estrogen-sensitive breast cancer cells.
The gene for 17 beta-hydroxysteroid dehydrogenase maps to human chromosome 17, bands q12-q21, and shows an RFLP with ScaI.
The regulation and inhibition of 17beta-hydroxysteroid dehydrogenase in breast cancer.
Two non-reactive ternary complexes of estrogenic 17beta-hydroxysteroid dehydrogenase: crystallization and preliminary structural analysis.
[Actions of a 19-norprogesterone derivative on mammary gland: nomegestrol acetate]
Carcinoma
17? hydroxysteroid dehydrogenase type 12 (HSD17B12) is a marker of poor prognosis in ovarian carcinoma.
17Beta-hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters.
17Beta-hydroxysteroid dehydrogenases in human endometrium and its disorders.
Characteristics of a highly labile human type 5 17beta-hydroxysteroid dehydrogenase.
High Expression of 17?-hydroxysteroid Dehydrogenase Type 2 is Associated with a Better Prognosis in Urothelial Carcinoma of the Urinary Tract.
Identification of Hydroxysteroid (17?) dehydrogenase type 12 (HSD17B12) as a CD8(+) T-cell-defined human tumor antigen of human carcinomas.
Immunological analysis of 17 beta-hydroxysteroid dehydrogenase in benign and malignant human breast tissue.
The analyses of 17beta-hydroxysteroid dehydrogenase isozymes in human endometrial hyperplasia and carcinoma.
[Altered expression of the HSD17B4 gene in esophageal squamous cell carcinoma and loss of heterozygosity analysis]
Carcinoma, Ductal
17Beta-hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters.
New development in intracrinology of breast carcinoma.
Carcinoma, Endometrioid
The analyses of 17beta-hydroxysteroid dehydrogenase isozymes in human endometrial hyperplasia and carcinoma.
Carcinoma, Hepatocellular
17Beta-hydroxysteroid dehydrogenase type 2 and dehydroepiandrosterone sulfotransferase in the human liver.
Association of Genetic Polymorphisms in HSD17B1, HSD17B2 and SHBG Genes with Hepatocellular Carcinoma Risk.
NF-?B increased expression of 17?-hydroxysteroid dehydrogenase 4 promotes HepG2 proliferation via inactivating estradiol.
Carcinoma, Intraductal, Noninfiltrating
Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast.
New development in intracrinology of breast carcinoma.
Carcinoma, Squamous Cell
Identification of Hydroxysteroid (17?) dehydrogenase type 12 (HSD17B12) as a CD8(+) T-cell-defined human tumor antigen of human carcinomas.
Intracellular regulation of 17 beta-hydroxysteroid dehydrogenase type 2 catalytic activity in A431 cells.
[Altered expression of the HSD17B4 gene in esophageal squamous cell carcinoma and loss of heterozygosity analysis]
Cerebellar Ataxia
Slowly progressive d-bifunctional protein deficiency with survival to adulthood diagnosed by whole-exome sequencing.
CHARGE Syndrome
Laser-capture micro dissection combined with next-generation sequencing analysis of cell type-specific deafness gene expression in the mouse cochlea.
Choriocarcinoma
Characterization of 17 beta-hydroxysteroid dehydrogenase type 1 in choriocarcinoma cells: regulation by basic fibroblast growth factor.
Endocrine disruption induced by organotin compounds; organotins function as a powerful agonist for nuclear receptors rather than an aromatase inhibitor.
Organotin compounds enhance 17beta-hydroxysteroid dehydrogenase type I activity in human choriocarcinoma JAr cells: potential promotion of 17beta-estradiol biosynthesis in human placenta.
The proximal promoter region of the gene encoding human 17beta-hydroxysteroid dehydrogenase type 1 contains GATA, AP-2, and Sp1 response elements: analysis of promoter function in choriocarcinoma cells.
Colonic Neoplasms
17Beta-hydroxysteroid dehydrogenase type 2: independent prognostic significance and evidence of estrogen protection in female patients with colon cancer.
Colorectal Neoplasms
Association of genetic polymorphisms in ESR2, HSD17B1, ABCB1, and SHBG genes with colorectal cancer risk.
Genetic variation in sex-steroid receptors and synthesizing enzymes and colorectal cancer risk in women.
Cysts
Private inherited microdeletion/microduplications: implications in clinical practice.
Diabetes Mellitus
[Serum levels of 17-beta estradiol dehydrogenase in pregnancies complicated by diabetes mellitus]
Down Syndrome
Polymorphisms in HSD17B1: Early Onset and Increased Risk of Alzheimer's Disease in Women with Down Syndrome.
Dyslipidemias
Role of dipeptidyl peptidase IV (DPP4) in the development of dyslipidemia: DPP4 contributes to the steroid metabolism pathway.
Endometrial Hyperplasia
Novel hydroxysteroid (17beta) dehydrogenase 1 inhibitors reverse estrogen-induced endometrial hyperplasia in transgenic mice.
The analyses of 17beta-hydroxysteroid dehydrogenase isozymes in human endometrial hyperplasia and carcinoma.
Endometrial Neoplasms
17Beta-hydroxysteroid dehydrogenases in human endometrium and its disorders.
Association between HSD17B1 rs605059 polymorphisms and the risk of uterine diseases: a systemic review and meta-analysis.
Divergent effects of retinoic acids on the expression of ERalpha and 17beta-hydroxysteroid dehydrogenase type 2 in endometrial carcinoma cells (RL 95-2).
Failure of progestins to induce estradiol dehydrogenase activity in endometrial carcinoma, in vitro.
Hormone replacement therapy and cancers: the biological roles of estrogen and progestin in tumorigenesis are different between the endometrium and breast.
Interaction of soy and 17beta-HSD1 gene polymorphisms in the risk of endometrial cancer.
Menopausal endocrinology and management.
Progestins and cancer.
The analyses of 17beta-hydroxysteroid dehydrogenase isozymes in human endometrial hyperplasia and carcinoma.
The correlation between the response to progestogen treatment and the expression of progesterone receptor B and 17beta-hydroxysteroid dehydrogenase type 2 in human endometrial carcinoma.
[Studies on estradiol dehydrogenase activity in the human uterine endometrium]
Endometriosis
Adenomyosis: the pathophysiology of an oestrogen-dependent disease.
Analysis of aromatase and 17beta-hydroxysteroid dehydrogenase type 2 messenger ribonucleic acid expression in deep endometriosis and eutopic endometrium using laser capture microdissection.
Association between endometriosis and genetic polymorphisms of the estradiol-synthesizing enzyme genes HSD17B1 and CYP19.
Association between HSD17B1 rs605059 polymorphisms and the risk of uterine diseases: a systemic review and meta-analysis.
Association of endometriosis risk and genetic polymorphisms involving biosynthesis of sex steroids and their receptors: an updating meta-analysis.
Deficient 17beta-hydroxysteroid dehydrogenase type 2 expression in endometriosis: failure to metabolize 17beta-estradiol.
Differential expression of genes in eutopic and ectopic endometrium from patients with ovarian endometriosis.
Effects of progestins on local estradiol biosynthesis and action in the Z-12 endometriotic epithelial cell line.
Endometriosis: the ultimate hormonal disease.
Estrogen biosynthesis in endometriosis: molecular basis and clinical relevance.
Estrogen metabolizing enzymes in endometrium and endometriosis.
Estrogen production and metabolism in endometriosis.
Estrone C15 derivatives--a new class of 17beta-hydroxysteroid dehydrogenase type 1 inhibitors.
Expression of 17beta-hydroxysteroid dehydrogenase type 2 in pelvic endometriosis.
Induction of endometriosis in the marmoset monkey (Callithrix jacchus).
Inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
Mechanisms of excessive estrogen formation in endometriosis.
Polymorphisms in ESR1, ESR2 and HSD17B1 genes are associated with fertility status in endometriosis.
Role of aromatase in endometrial disease.
Species used for drug testing reveal different inhibition susceptibility for 17beta-hydroxysteroid dehydrogenase type 1.
Steroidogenic enzyme and key decidualization marker dysregulation in endometrial stromal cells from women with versus without endometriosis.
Stromal cells of endometriosis fail to produce paracrine factors that induce epithelial 17beta-hydroxysteroid dehydrogenase type 2 gene and its transcriptional regulator Sp1: a mechanism for defective estradiol metabolism.
The role of the heterocycle in bis(hydroxyphenyl)triazoles for inhibition of 17beta-Hydroxysteroid Dehydrogenase (17beta-HSD) type 1 and type 2.
Goiter
Estrogen receptors (alpha and beta) and 17beta-hydroxysteroid dehydrogenase type 1 and 2 in thyroid disorders: possible in situ estrogen synthesis and actions.
Hearing Loss
Laser-capture micro dissection combined with next-generation sequencing analysis of cell type-specific deafness gene expression in the mouse cochlea.
Mutations in the DBP-deficiency protein HSD17B4 cause ovarian dysgenesis, hearing loss, and ataxia of Perrault Syndrome.
Next generation sequencing with copy number variant detection expands the phenotypic spectrum of HSD17B4-deficiency.
Hepatitis, Chronic
17Beta-hydroxysteroid dehydrogenase type 2 and dehydroepiandrosterone sulfotransferase in the human liver.
Hydatidiform Mole
[Serum and tissue 17 beta hydroxysteroid dehydrogenase and estrogens in hydatidiform mole]
[Serum levels of 17-beta estradiol dehydrogenase in pregnancies complicated by hydatidiform mole and in twin pregnancies]
Hypertension
Plasma level of hydroxysteroid (17-?) dehydrogenase 1 in the second trimester is an independent risk factor for predicting preeclampsia after adjusting for the effects of mean blood pressure, bilateral notching and plasma level of soluble fms-like tyrosine kinase 1/placental growth factor ratio.
Hypospadias
Fine mapping analysis confirms and strengthens linkage of four chromosomal regions in familial hypospadias.
Lack of defects in androgen production in children with hypospadias.
Infertility
Polymorphisms in ESR1, ESR2 and HSD17B1 genes are associated with fertility status in endometriosis.
The hydroxysteroid (17?) dehydrogenase family gene HSD17B12 is involved in the prostaglandin synthesis pathway, the ovarian function, and regulation of fertility.
Transgenic male mice expressing human hydroxysteroid dehydrogenase 2 indicate a role for the enzyme independent of its action on sex steroids.
Intellectual Disability
Severe manifestation of Leber's hereditary optic neuropathy due to 11778G>A mtDNA mutation in a female with hypoestrogenism due to Perrault syndrome.
Kallmann Syndrome
Laser-capture micro dissection combined with next-generation sequencing analysis of cell type-specific deafness gene expression in the mouse cochlea.
Leiomyoma
Adenomyosis: the pathophysiology of an oestrogen-dependent disease.
Association between HSD17B1 rs605059 polymorphisms and the risk of uterine diseases: a systemic review and meta-analysis.
Increased expression of type I 17beta-hydroxysteroid dehydrogenase enhances in situ production of estradiol in uterine leiomyoma.
Polymorphisms in genes HSD17B1 and HSD17B2 and uterine leiomyoma risk in Chinese women.
Leukemia
T cell recognition of Moloney leukemia virus proteins. III. T cell proliferative responses against gp70 are associated with the production of a lymphokine inducing 20 alpha-hydroxysteroid dehydrogenase in splenic lymphocytes.
Liver Diseases, Alcoholic
Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde reductase and the principal human aldo-keto reductase AKR1 family members.
Liver Neoplasms
NF-?B increased expression of 17?-hydroxysteroid dehydrogenase 4 promotes HepG2 proliferation via inactivating estradiol.
Lymphoma
Influence of genotype and the organ of origin on the subtype of T-cell in Moloney lymphomas induced by transfer of preleukemic cells from athymic and thymus-bearing mice.
Mandibulofacial Dysostosis
Laser-capture micro dissection combined with next-generation sequencing analysis of cell type-specific deafness gene expression in the mouse cochlea.
Neoplasm Metastasis
Expression of 17?-hydroxysteroid dehydrogenase type 2 is associated with some clinicopathological features in gastric cancer.
High Expression of 17?-hydroxysteroid Dehydrogenase Type 2 is Associated with a Better Prognosis in Urothelial Carcinoma of the Urinary Tract.
High expression of steroid sulfatase mRNA predicts poor prognosis in patients with estrogen receptor-positive breast cancer.
Steroid-converting enzymes in human ovarian carcinomas.
Neoplasms
17? hydroxysteroid dehydrogenase type 12 (HSD17B12) is a marker of poor prognosis in ovarian carcinoma.
17Beta-hydroxysteroid dehydrogenase enzymes and breast cancer.
17Beta-hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters.
17beta-hydroxysteroid dehydrogenase type 1 is an independent prognostic marker in breast cancer.
17Beta-hydroxysteroid dehydrogenase type 1, 2, 3, and 4 expression and enzyme activity in human anterior pituitary adenomas.
17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer.
17Beta-hydroxysteroid dehydrogenase type 12 in human breast carcinoma: a prognostic factor via potential regulation of fatty acid synthesis.
17ss-Hydroxysteroid dehydrogenase type 1 as predictor of tamoxifen response in premenopausal breast cancer.
20 alpha-hydroxysteroid dehydrogenase activity in canine spontaneous neoplasms.
A low carbohydrate, high protein diet suppresses intratumoral androgen synthesis and slows castration-resistant prostate tumor growth in mice.
Amplification of HSD17B1 and ERBB2 in primary breast cancer.
Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer.
Cytosol and nuclear estrogen and progestin receptors and 17 beta-hydroxysteroid dehydrogenase activity in non-diseased tissue and in benign and malignant tumors of the human ovary.
Cytosolic 20 alpha-hydroxysteroid dehydrogenase activity in spontaneous neoplasms in the dog and cat.
Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase Type 3.
Differential expression of 17beta-hydroxysteroid dehydrogenase isozyme genes in prostate cancer and noncancer tissues.
Effect modification of endocrine disruptors and testicular germ cell tumour risk by hormone-metabolizing genes.
Estradiol and estrone C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: blocking of ER+ breast cancer cell proliferation induced by estrone.
Estradiol-adenosine hybrid compounds designed to inhibit type 1 17beta-hydroxysteroid dehydrogenase.
Expression of 17?-hydroxysteroid dehydrogenase type 2 is associated with some clinicopathological features in gastric cancer.
Expression of 17beta-hydroxysteroid dehydrogenase type 2 and type 5 in breast cancer and adjacent non-malignant tissue: a correlation to clinicopathological parameters.
Expression of 17beta-hydroxysteroid dehydrogenases and other estrogen-metabolizing enzymes in different cancer cell lines.
Expression of aromatase and 17beta-hydroxysteroid dehydrogenase types 1, 7 and 12 in breast cancer An immunocytochemical study.
Gene expression of androgen metabolising enzymes in benign prostatic hyperplasia.
Genetic Variation in the HSD17B1 Gene and Risk of Prostate Cancer.
Haplotype analysis of the HSD17B1 gene and risk of breast cancer: a comprehensive approach to multicenter analyses of prospective cohort studies.
High expression of steroid sulfatase mRNA predicts poor prognosis in patients with estrogen receptor-positive breast cancer.
HSD17B1 gene polymorphisms and risk of endometrial and breast cancer.
Human hydroxysteroid (17-beta) dehydrogenase 1 expression enhances estrogen sensitivity of MCF-7 breast cancer cell xenografts.
Identification of a 17beta-hydroxysteroid dehydrogenase type 12 pseudogene as the source of a highly restricted BALB/c Meth A tumor rejection peptide.
Identification of Hydroxysteroid (17?) dehydrogenase type 12 (HSD17B12) as a CD8(+) T-cell-defined human tumor antigen of human carcinomas.
Immunological analysis of 17 beta-hydroxysteroid dehydrogenase in benign and malignant human breast tissue.
In vivo and in vitro expression of steroid-converting enzymes in human breast tumours: associations with interleukin-6.
In vivo mouse model for analysis of hydroxysteroid (17beta) dehydrogenase 1 inhibitors.
Involvement of H-cadherin (CDH13) on 16q in the region of frequent deletion in ovarian cancer.
Involvement of up-regulation of 17beta-hydroxysteroid dehydrogenase type 1 in maintenance of intratumoral high estradiol levels in postmenopausal breast cancers.
Mammalian lignans and genistein decrease the activities of aromatase and 17beta-hydroxysteroid dehydrogenase in MCF-7 cells.
Molecular Framework of Steroid/Retinoid Discrimination in 17beta-Hydroxysteroid Dehydrogenase Type 1 and Photoreceptor-associated Retinol Dehydrogenase.
New Insights into the SAR and Binding Modes of Bis(hydroxyphenyl)thiophenes and -benzenes: Influence of Additional Substituents on 17beta-Hydroxysteroid Dehydrogenase Type 1 (17beta-HSD1) Inhibitory Activity and Selectivity.
NF-?B increased expression of 17?-hydroxysteroid dehydrogenase 4 promotes HepG2 proliferation via inactivating estradiol.
Polymorphism of HSD17B1 Ser312Gly with Cancer Risk: Evidence from 66,147 Subjects.
Quantitative analysis of the human AKR family members in cancer cell lines using the mTRAQ/MRM approach.
Ratio of 17HSD1 to 17HSD2 Protein Expression Predicts the Outcome of Tamoxifen Treatment in Postmenopausal Breast Cancer Patients.
Reductive 17beta-hydroxysteroid dehydrogenases in the sulfatase pathway: critical in the cell proliferation of breast cancer.
Role of BRCA1, HSD17B1 and HSD17B2 methylation in breast cancer tissue.
Steroid metabolism and steroid receptors in dimethylbenz(a)anthracene-induced rat mammary tumors.
Steroid metabolism in normal mammary gland and in the dimethylbenzanthracene-induced mammary tumor of rats.
Steroid-converting enzymes in human ovarian carcinomas.
Structure-based design, synthesis and in vitro characterization of potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors based on 2-substitutions of estrone and D-homo-estrone.
The prognostic impact of lipid biosynthesis-associated markers, HSD17B2 and HMGCS2, in rectal cancer treated with neoadjuvant concurrent chemoradiotherapy.
The role of the heterocycle in bis(hydroxyphenyl)triazoles for inhibition of 17beta-Hydroxysteroid Dehydrogenase (17beta-HSD) type 1 and type 2.
Unusual charge stabilization of NADP+ in 17beta-hydroxysteroid dehydrogenase.
[Altered expression of the HSD17B4 gene in esophageal squamous cell carcinoma and loss of heterozygosity analysis]
Nephritis, Hereditary
Laser-capture micro dissection combined with next-generation sequencing analysis of cell type-specific deafness gene expression in the mouse cochlea.
Neuroblastoma
Common genetic variants in NEFL influence gene expression and neuroblastoma risk.
Replication of GWAS-identified neuroblastoma risk loci strengthens the role of BARD1 and affirms the cumulative effect of genetic variations on disease susceptibility.
Osteosarcoma
Effects of 20 alpha-hydroxysteroid dehydrogenase and its inhibitors on canine osteosarcoma cell growth in vitro.
Ovarian Neoplasms
Characterization of HSD17B1 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer.
Inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
Mutation analysis and characterization of HSD17B2 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer.
Peripheral Nervous System Diseases
Slowly progressive d-bifunctional protein deficiency with survival to adulthood diagnosed by whole-exome sequencing.
Pituitary Neoplasms
17Beta-hydroxysteroid dehydrogenase type 1, 2, 3, and 4 expression and enzyme activity in human anterior pituitary adenomas.
Pregnancy, Tubal
Expression of P450 aromatase and 17beta-hydroxysteroid dehydrogenase type 1 at fetal-maternal interface during tubal pregnancy.
Primary Ovarian Insufficiency
Epistasis between the HSD17B4 and TG polymorphisms is associated with premature ovarian failure.
Prolactinoma
17Beta-hydroxysteroid dehydrogenase type 1, 2, 3, and 4 expression and enzyme activity in human anterior pituitary adenomas.
Prostatic Neoplasms
Allelic loss of the loci containing the androgen synthesis gene, StAR, is prognostic for relapse in intermediate-risk prostate cancer.
Characteristics of a highly labile human type 5 17beta-hydroxysteroid dehydrogenase.
Differential expression of 17beta-hydroxysteroid dehydrogenase isozyme genes in prostate cancer and noncancer tissues.
Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer.
Expression of different 17beta-hydroxysteroid dehydrogenase types and their activities in human prostate cancer cells.
Genetic Variation in the HSD17B1 Gene and Risk of Prostate Cancer.
HSD17B4 overexpression, an independent biomarker of poor patient outcome in prostate cancer.
Regulation of 17beta-hydroxysteroid dehydrogenase type 2, type 4 and type 5 by calcitriol, LXR agonist and 5alpha-dihydrotestosterone in human prostate cancer cells.
Steroidogenic enzymes and stem cell markers are up-regulated during androgen deprivation in prostate cancer.
Protein Deficiency
D-bifunctional protein deficiency: a cause of neonatal onset seizures and hypotonia.
Diagnosis of D-Bifunctional Protein Deficiency through Whole-Genome Sequencing: Implications for Cost-Effective Care.
Heterozygous mutations in HSD17B4 cause juvenile peroxisomal D-bifunctional protein deficiency.
Next generation sequencing with copy number variant detection expands the phenotypic spectrum of HSD17B4-deficiency.
Rectal Neoplasms
The prognostic impact of lipid biosynthesis-associated markers, HSD17B2 and HMGCS2, in rectal cancer treated with neoadjuvant concurrent chemoradiotherapy.
Sarcoma
Identification of a 17beta-hydroxysteroid dehydrogenase type 12 pseudogene as the source of a highly restricted BALB/c Meth A tumor rejection peptide.
Seizures
Diagnosis of D-Bifunctional Protein Deficiency through Whole-Genome Sequencing: Implications for Cost-Effective Care.
Stomach Neoplasms
Expression of 17?-hydroxysteroid dehydrogenase type 1 in gastric cancer.
Genetic susceptibility factors on genes involved in the steroid hormone biosynthesis pathway and progesterone receptor for gastric cancer risk.
Polymorphisms in estrogen- and androgen-metabolizing genes and the risk of gastric cancer.
Thymoma
Estrogen inhibits cell proliferation through in situ production in human thymoma.
Uremia
Different vitamin D receptor agonists exhibit differential effects on endothelial function and aortic gene expression in 5/6 nephrectomized rats.
Usher Syndromes
Laser-capture micro dissection combined with next-generation sequencing analysis of cell type-specific deafness gene expression in the mouse cochlea.
Uterine Cervical Neoplasms
Increased 17ß-hydroxysteroid dehydrogenase type 1 levels in primary cervical cancer.
Uterine Diseases
Association between HSD17B1 rs605059 polymorphisms and the risk of uterine diseases: a systemic review and meta-analysis.
Novel hydroxysteroid (17beta) dehydrogenase 1 inhibitors reverse estrogen-induced endometrial hyperplasia in transgenic mice.
Uterine Hemorrhage
Menopausal endocrinology and management.
Waardenburg Syndrome
Laser-capture micro dissection combined with next-generation sequencing analysis of cell type-specific deafness gene expression in the mouse cochlea.
Zellweger Syndrome
Unique multifunctional HSD17B4 gene product: 17beta-hydroxysteroid dehydrogenase 4 and D-3-hydroxyacyl-coenzyme A dehydrogenase/hydratase involved in Zellweger syndrome.